{"id":197062,"name":"GOVERNMENT COUNSEL, LLC (OBO) LUPIN PHARMACEUTICALS, INC.","slug":"government-counsel-llc-obo-lupin-pharmaceuticals-inc","state":"FL","country":"United States of America","description":"&#226;€‹Public Policy and Government Advisory Firm","totalSpending":120000,"filings":9,"yearlySpending":[{"year":2019,"income":40000},{"year":2020,"income":80000}],"issues":["HCR"],"firms":["HOOPER, LUNDY & BOOKMAN, P.C."],"lobbyists":["MARTIN CORRY","LISA LAYMAN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Electronic drug labeling, drug take back program and USPTO inter partes review procedure.","The Lower Health Care Costs Act of 2019 (S. 1895), Provisions related to Hatch-Waxman 180-day exclusivity periods; Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (","The Lower Health Care Costs Act of 2019 (S. 1895), Provisions related to Hatch-Waxman 180-day exclusivity periods; Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (","The Lower Health Care Costs Act of 2019 (S. 1895), Provisions related to Hatch-Waxman 180-day exclusivity periods; Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (","The Blocking Act (H.R. 938); Strengthening Health Care and Lowering Prescription Drug Costs (H.R. 987); Lower Health Care Costs Act (Sec.205) (S. 1895)."],"years":[2019,2020]}